Posted in | News | Remote Monitoring

Samsung Mobile Joins Forces with Preventice on BodyGuardian Remote Monitoring System

Samsung Telecommunications America, LLC (Samsung Mobile)1 and Preventice™, a leading developer of mobile health solutions and remote monitoring systems, announced today that Samsung will provide mobile phones for the new BodyGuardian Remote Monitoring System (RMS)™ from Preventice. Preventice recently announced its receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BodyGuardian RMS, allowing Preventice to market and sell BodyGuardian to hospitals and clinics for use in detecting and monitoring non-lethal cardiac arrhythmias for ambulatory patients.

Samsung Mobile, one of the world's largest providers of telecommunications products and technologies, has made a commitment to collaborating with health technology companies in an effort to develop for its leading consumer devices new use cases that ultimately improve the quality of patients' lives.

"Samsung Mobile is thrilled to join forces with Preventice on its BodyGuardian system, freeing patients from expensive and time-consuming office visits," said Timothy K. Wagner, vice president and general manager, Samsung Mobile. "With a strong portfolio of secure, dependable, and feature-rich smartphones and tablets, Samsung Mobile is increasingly playing a key role in delivering innovative solutions within the health care industry and beyond."

The BodyGuardian System will enable physicians to monitor key biometrics in patients with cardiac arrhythmias outside of the clinical setting, allowing patients go about their daily lives while remaining connected to their physicians. According to Preventice, Samsung Mobile will customize the Galaxy S II smartphone for use in the BodyGuardian RMS by creating a dedicated mobile environment that will ensure a secure, reliable wireless connection for the transmission of biometric data. Patient data is captured using a small wearable sensor and delivered via Bluetooth communication to a dedicated Galaxy S II smartphone. The Galaxy S II then transmits the physiological data via cellular network to the Preventice Care Platform in the cloud. Physicians and/or monitoring centers then access the data via a web or tablet-based portal.

"Remote patient monitoring will significantly change the way patients with heart disease and a variety of other chronic conditions experience the health care system, but only if we're able to provide solutions that meet the strictest of standards for patient protection and clinical performance," said Jon Otterstatter, co-founder, president and CEO of Preventice. "By collaborating with Samsung, we are able to create a dedicated mobile environment that brings sophisticated, secure and reliable, remote patient monitoring to patients where they live, work and play."

The potential for remote patient monitoring to reduce patient costs and influence care delivery is contributing to rapid growth in the use of wireless monitoring, which is expected to continue in the coming years. In fact, recent research from Kalorama shows that the U.S. market for advanced patient monitoring systems has grown from $3.9 billion in 2007, to $8.9 billion in 2011. The market is expected to reach $20.9 billion by 2016, according to this same study.

1 Samsung Mobile is the No. 1 mobile phone provider in the United States based upon reported shipment data, according to Strategy Analytics, North America Handset Vendor Marketshare, Q3 2012.

Samsung and Galaxy S are trademarks of Samsung Electronics Co., Ltd. Android is a trademark of Google Inc. Other company names, product names and marks mentioned herein are property of their respective owners and may be trademarks or registered trademarks.

Source: http://www.preventice.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.